Neurotrophic Keratopathy Clinical Trial
Official title:
Topical Insulin in Treatment of Neurotrophic Corneal Ulcer,Efficacy And Safety
To evaluate Safety and efficacy of topical insulin in treatment of neurotrophic corneal ulcers
Neurotrophic keratopathy is a degenerative disease of the corneal epithelium resulting from impaired corneal innervation. A reduction In corneal sensitivity or complete corneal anesthesia is the hallmark of this disease and is responsible for producing epithelial keratopathy, ulceration and perforation. Because decreased corneal sensitivity is the hallmark sign of neurotrophic keratitis (NK), corneal sensitivity testing should be performed as soon as It is suspected There are 2 common ways to test-one qualitative, the other quantitative: The qualitative method is most commonly used In clinic and often achieved with a cotton tipped applicator because It is easily accessible. The most common quantitative method is the handheld esthesiometer (Cochet-Bonnet). Standard treatment of neurotrophic corneal ulcer involves aggressive lubrication of the corneal surface, therapeutic contact lenses, amniotic membrane grafts and tarsorrhaphy . Refractory neurotrophic corneal ulcers occur when treatment response is incomplete and are potentially blinding. Insulin is a widely available, relatively safe, and familiar medication that has been shown to improve corneal epithelial healing In vitro and in diabetic animal models. However, clinical experience with topical insulin in patients with non-healing corneal wounds is minimal. Insulin-like growth factor-1 (IGF-1) has been shown to be an important modulator of corneal wound healing. Topical insulin may be a simple and effective treatment for neurotrophic corneal ulcers. The main outcome measurements for improvement are the decrease of ulcer size by fluroscien stain,the increase in visual acuity. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02600429 -
Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1
|
Phase 3 | |
| Recruiting |
NCT04604834 -
Autologous Platelet-rich Plasma (APRP) in the Treatment of Neurotrophic Keratopathy
|
N/A | |
| Not yet recruiting |
NCT06412718 -
Validation of Human Drugs Target of Repurposed Drugs and Novel Therapies
|
||
| Completed |
NCT04293549 -
An 8-week Follow-up to Evaluate the Renewal of Corneal Nerves Structure and Function in Patients With Neurotrophic Keratopathy Treated With Recombinant Human Nerve Growth Factor (rhNGF) Eyedrops
|
||
| Completed |
NCT04957758 -
Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
|
Phase 2 | |
| Terminated |
NCT03084861 -
A Clinical Trial to Asses Efficacy and Safety of Cord Blood Eye Drops in Neurotrophic Keratopathy
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT06411145 -
Open-label Trial to Evaluate Efficacy and Safety of rhNGF on Corneal Thickness Via AS-OCT in Neurotrophic Keratitis
|
Phase 4 | |
| Recruiting |
NCT05555589 -
Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2
|
Phase 3 |